Engineered CARD11-PIK3R3 T-cell therapies as weapons of cancer mass destruction.
MedComm (2020)
; 5(7): e628, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38952574
ABSTRACT
Garcia et al. discover a novel immunotherapy approach by engineering naturally occurring mutations in therapeutic T cells to strongly elevate anti-tumor activity. The authors identify a gene fusion, CARD11-PIK3R3, to increase activator protein 1 and nuclear factor-κB signaling, interleukin-2 production, and tumor death in vitro and in vivo .
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
/
Tipos_de_cancer
/
Outros_tipos
Base de dados:
MEDLINE
Idioma:
En
Revista:
MedComm (2020)
Ano de publicação:
2024
Tipo de documento:
Article